2026 Q2 - tulosraportti
62 päivää sitten
‧32 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 18 | - | - | ||
| 193 | - | - | ||
| 4 | - | - | ||
| 12 040 | - | - | ||
| 540 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 19.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 21.5. | ||
2025 Q4 - tulosraportti 26.3. | ||
2025 Q3 - tulosraportti 19.11.2025 | ||
2025 Q2 - tulosraportti 15.8.2025 |
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·5 t sittenIt is very interesting that professor, Dr. Med, Jun Oh’s independent presentation on October 7, 2026 at BioPorto in Copenhagen is now available. He presented NGAL as a necessary paradigm shift in everyday clinical practice: Until now, the global KDIGO guidelines (which have not been updated since 2012) have effectively overlooked biomarkers. Without an official KDIGO recommendation, the NGAL test has merely been seen as a "nice-to-have" supplementary research tool rather than a clinical requirement. That is only changing now with the new guidelines in late 2026. * Catalyst for adoption: When an independent KOL of his caliber adopts a product and speaks warmly of it, it creates a "snowball effect". Other hospitals and physicians worldwide trust a respected professor colleague far more than a sales signal from BioPorto itself, which accelerates adoption. * Strengthening the commercial case: His open interest and data support, as well as thorough assessment of the need where his slides show the need for NGAL (the size of the potential market for NGAL), validate the market potential toward major distribution partners (such as Roche and Beckman Coulter). It removes commercial skepticism and shows investors that BioPorto's test is not just "a smart idea", but a real tool that is already being integrated at top European hospitals. He assesses the need for the NGAL test as critical and acute. He has emphasized this by stating that he now uses the NGAL test routinely in his own department to catch kidney injuries in time and save patients from dialysis. Dr. Jun Oh is precisely the type of top clinician whose professional stamping of approval pharmaceutical and diagnostics companies dream of having behind them: * International heavyweight: He is a highly respected name at international medical conferences and is a Council Member in the two leading professional societies: European Society for Paediatric Nephrology (ESPN) and Gesellschaft für Pädiatrische Nephrologie (GPN). * Expert in European networks: Dr. Jun Oh has been appointed as official clinical expert and coordinator in the European Reference Network for Rare Kidney Diseases (ERKNet). This network sets the standard for the treatment of rare kidney diseases throughout Europe. * Focus on guidelines: Due to his broad engagement in randomized clinical trials and patient registries, he is one of the key figures whose professional assessments carry heavy weight when new clinical guidelines (including KDIGO) are formulated and presented at conferences. His absolute specialty is paediatric nephrology (kidney diseases in children) and organ transplantations. He leads one of Europe's largest transplantation programs for infants and children. He has published over 100 original scientific articles (“peer reviewed publications”). *The presentation: https://www.inderes.dk/en/videos/bioporto-from-reaction-to-prevention-in-aki?utm_source=nordnet&utm_medium=integrationWith the limited funds that BioPorto currently has at its disposal, it is a sensible, but not optimal solution for a publicly traded company. Thought-provoking ?
·9 t sittenHow wonderful to hear all your negative information that affects the share price. Hope you have sold your shares.
·2 päivää sittenAnalyst comment 19.10.2026, 08.54 Victor Skriver Equity Research Assistant At BioPorto's investor meeting on 7 October, Professor Dr. Jun Oh from Heidelberg University Hospital gave an independent clinical perspective on what the updated KDIGO guidelines mean for NGAL. His point was that nephrology is moving from reaction towards prevention, and that is precisely the shift upon which the investment case rests. Oh's presentation speaks directly into the second pillar of our investment case, where inclusion in KDIGO is the trigger for broader adoption in hospitals, and it supports the health economics angle, which we see as the most overlooked part of the case. BioPorto: From reaction to prevention in acute myocardial infarction - by Michael Friis, Head of Equities https://www.inderes.dk/videos/bioporto-from-reaction-to-prevention-in-aki Victor Skriver Equity Research Assistant https://www.inderes.dk/analyst-comments/dagens-aktienyheder-19102026-lundbeck-nordea-bioporto-og-greenmobility?utm_source=nordnet&utm_medium=integrationFor about 5 years you have now “covered “ bioporto. In those 5 years you have not sent a single critical post, which is remarkable given that the stock has fallen 75% in that period, so everything can not have gone super well. For 5 years you have only sent one-sided positive posts. Conservatively put you have probably written 1 post/day. That corresponds to 2000 extremely positive posts, where you often, again and again and countless times have predicted imminent large price increases. But nothing has happened. How long are you going to be wrong, how many thousand overly positive posts are you going to send before you realize that you cannot talk the share price up, before you realize your strategy is flawed? That your view on stocks is unrealistic and more based on dreams than facts becomes especially clear in stenocare. In only 2 months stenocare loses about half of its business, it simply disappears with the bankruptcy in Holland. But this life-threatening mega challenge you do not relate to at all, you are still sitting and telling about a pharmacy here or there that probably sells 1-2 units a week.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 128 540 | 128 540 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 128 540 | 128 540 | 0 | 0 |
2026 Q2 - tulosraportti
62 päivää sitten
‧32 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·5 t sittenIt is very interesting that professor, Dr. Med, Jun Oh’s independent presentation on October 7, 2026 at BioPorto in Copenhagen is now available. He presented NGAL as a necessary paradigm shift in everyday clinical practice: Until now, the global KDIGO guidelines (which have not been updated since 2012) have effectively overlooked biomarkers. Without an official KDIGO recommendation, the NGAL test has merely been seen as a "nice-to-have" supplementary research tool rather than a clinical requirement. That is only changing now with the new guidelines in late 2026. * Catalyst for adoption: When an independent KOL of his caliber adopts a product and speaks warmly of it, it creates a "snowball effect". Other hospitals and physicians worldwide trust a respected professor colleague far more than a sales signal from BioPorto itself, which accelerates adoption. * Strengthening the commercial case: His open interest and data support, as well as thorough assessment of the need where his slides show the need for NGAL (the size of the potential market for NGAL), validate the market potential toward major distribution partners (such as Roche and Beckman Coulter). It removes commercial skepticism and shows investors that BioPorto's test is not just "a smart idea", but a real tool that is already being integrated at top European hospitals. He assesses the need for the NGAL test as critical and acute. He has emphasized this by stating that he now uses the NGAL test routinely in his own department to catch kidney injuries in time and save patients from dialysis. Dr. Jun Oh is precisely the type of top clinician whose professional stamping of approval pharmaceutical and diagnostics companies dream of having behind them: * International heavyweight: He is a highly respected name at international medical conferences and is a Council Member in the two leading professional societies: European Society for Paediatric Nephrology (ESPN) and Gesellschaft für Pädiatrische Nephrologie (GPN). * Expert in European networks: Dr. Jun Oh has been appointed as official clinical expert and coordinator in the European Reference Network for Rare Kidney Diseases (ERKNet). This network sets the standard for the treatment of rare kidney diseases throughout Europe. * Focus on guidelines: Due to his broad engagement in randomized clinical trials and patient registries, he is one of the key figures whose professional assessments carry heavy weight when new clinical guidelines (including KDIGO) are formulated and presented at conferences. His absolute specialty is paediatric nephrology (kidney diseases in children) and organ transplantations. He leads one of Europe's largest transplantation programs for infants and children. He has published over 100 original scientific articles (“peer reviewed publications”). *The presentation: https://www.inderes.dk/en/videos/bioporto-from-reaction-to-prevention-in-aki?utm_source=nordnet&utm_medium=integrationWith the limited funds that BioPorto currently has at its disposal, it is a sensible, but not optimal solution for a publicly traded company. Thought-provoking ?
- ·9 t sittenHow wonderful to hear all your negative information that affects the share price. Hope you have sold your shares.
- ·2 päivää sittenAnalyst comment 19.10.2026, 08.54 Victor Skriver Equity Research Assistant At BioPorto's investor meeting on 7 October, Professor Dr. Jun Oh from Heidelberg University Hospital gave an independent clinical perspective on what the updated KDIGO guidelines mean for NGAL. His point was that nephrology is moving from reaction towards prevention, and that is precisely the shift upon which the investment case rests. Oh's presentation speaks directly into the second pillar of our investment case, where inclusion in KDIGO is the trigger for broader adoption in hospitals, and it supports the health economics angle, which we see as the most overlooked part of the case. BioPorto: From reaction to prevention in acute myocardial infarction - by Michael Friis, Head of Equities https://www.inderes.dk/videos/bioporto-from-reaction-to-prevention-in-aki Victor Skriver Equity Research Assistant https://www.inderes.dk/analyst-comments/dagens-aktienyheder-19102026-lundbeck-nordea-bioporto-og-greenmobility?utm_source=nordnet&utm_medium=integrationFor about 5 years you have now “covered “ bioporto. In those 5 years you have not sent a single critical post, which is remarkable given that the stock has fallen 75% in that period, so everything can not have gone super well. For 5 years you have only sent one-sided positive posts. Conservatively put you have probably written 1 post/day. That corresponds to 2000 extremely positive posts, where you often, again and again and countless times have predicted imminent large price increases. But nothing has happened. How long are you going to be wrong, how many thousand overly positive posts are you going to send before you realize that you cannot talk the share price up, before you realize your strategy is flawed? That your view on stocks is unrealistic and more based on dreams than facts becomes especially clear in stenocare. In only 2 months stenocare loses about half of its business, it simply disappears with the bankruptcy in Holland. But this life-threatening mega challenge you do not relate to at all, you are still sitting and telling about a pharmacy here or there that probably sells 1-2 units a week.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 18 | - | - | ||
| 193 | - | - | ||
| 4 | - | - | ||
| 12 040 | - | - | ||
| 540 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 19.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 21.5. | ||
2025 Q4 - tulosraportti 26.3. | ||
2025 Q3 - tulosraportti 19.11.2025 | ||
2025 Q2 - tulosraportti 15.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 128 540 | 128 540 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 128 540 | 128 540 | 0 | 0 |
2026 Q2 - tulosraportti
62 päivää sitten
‧32 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 19.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 21.5. | ||
2025 Q4 - tulosraportti 26.3. | ||
2025 Q3 - tulosraportti 19.11.2025 | ||
2025 Q2 - tulosraportti 15.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·5 t sittenIt is very interesting that professor, Dr. Med, Jun Oh’s independent presentation on October 7, 2026 at BioPorto in Copenhagen is now available. He presented NGAL as a necessary paradigm shift in everyday clinical practice: Until now, the global KDIGO guidelines (which have not been updated since 2012) have effectively overlooked biomarkers. Without an official KDIGO recommendation, the NGAL test has merely been seen as a "nice-to-have" supplementary research tool rather than a clinical requirement. That is only changing now with the new guidelines in late 2026. * Catalyst for adoption: When an independent KOL of his caliber adopts a product and speaks warmly of it, it creates a "snowball effect". Other hospitals and physicians worldwide trust a respected professor colleague far more than a sales signal from BioPorto itself, which accelerates adoption. * Strengthening the commercial case: His open interest and data support, as well as thorough assessment of the need where his slides show the need for NGAL (the size of the potential market for NGAL), validate the market potential toward major distribution partners (such as Roche and Beckman Coulter). It removes commercial skepticism and shows investors that BioPorto's test is not just "a smart idea", but a real tool that is already being integrated at top European hospitals. He assesses the need for the NGAL test as critical and acute. He has emphasized this by stating that he now uses the NGAL test routinely in his own department to catch kidney injuries in time and save patients from dialysis. Dr. Jun Oh is precisely the type of top clinician whose professional stamping of approval pharmaceutical and diagnostics companies dream of having behind them: * International heavyweight: He is a highly respected name at international medical conferences and is a Council Member in the two leading professional societies: European Society for Paediatric Nephrology (ESPN) and Gesellschaft für Pädiatrische Nephrologie (GPN). * Expert in European networks: Dr. Jun Oh has been appointed as official clinical expert and coordinator in the European Reference Network for Rare Kidney Diseases (ERKNet). This network sets the standard for the treatment of rare kidney diseases throughout Europe. * Focus on guidelines: Due to his broad engagement in randomized clinical trials and patient registries, he is one of the key figures whose professional assessments carry heavy weight when new clinical guidelines (including KDIGO) are formulated and presented at conferences. His absolute specialty is paediatric nephrology (kidney diseases in children) and organ transplantations. He leads one of Europe's largest transplantation programs for infants and children. He has published over 100 original scientific articles (“peer reviewed publications”). *The presentation: https://www.inderes.dk/en/videos/bioporto-from-reaction-to-prevention-in-aki?utm_source=nordnet&utm_medium=integrationWith the limited funds that BioPorto currently has at its disposal, it is a sensible, but not optimal solution for a publicly traded company. Thought-provoking ?
- ·9 t sittenHow wonderful to hear all your negative information that affects the share price. Hope you have sold your shares.
- ·2 päivää sittenAnalyst comment 19.10.2026, 08.54 Victor Skriver Equity Research Assistant At BioPorto's investor meeting on 7 October, Professor Dr. Jun Oh from Heidelberg University Hospital gave an independent clinical perspective on what the updated KDIGO guidelines mean for NGAL. His point was that nephrology is moving from reaction towards prevention, and that is precisely the shift upon which the investment case rests. Oh's presentation speaks directly into the second pillar of our investment case, where inclusion in KDIGO is the trigger for broader adoption in hospitals, and it supports the health economics angle, which we see as the most overlooked part of the case. BioPorto: From reaction to prevention in acute myocardial infarction - by Michael Friis, Head of Equities https://www.inderes.dk/videos/bioporto-from-reaction-to-prevention-in-aki Victor Skriver Equity Research Assistant https://www.inderes.dk/analyst-comments/dagens-aktienyheder-19102026-lundbeck-nordea-bioporto-og-greenmobility?utm_source=nordnet&utm_medium=integrationFor about 5 years you have now “covered “ bioporto. In those 5 years you have not sent a single critical post, which is remarkable given that the stock has fallen 75% in that period, so everything can not have gone super well. For 5 years you have only sent one-sided positive posts. Conservatively put you have probably written 1 post/day. That corresponds to 2000 extremely positive posts, where you often, again and again and countless times have predicted imminent large price increases. But nothing has happened. How long are you going to be wrong, how many thousand overly positive posts are you going to send before you realize that you cannot talk the share price up, before you realize your strategy is flawed? That your view on stocks is unrealistic and more based on dreams than facts becomes especially clear in stenocare. In only 2 months stenocare loses about half of its business, it simply disappears with the bankruptcy in Holland. But this life-threatening mega challenge you do not relate to at all, you are still sitting and telling about a pharmacy here or there that probably sells 1-2 units a week.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 18 | - | - | ||
| 193 | - | - | ||
| 4 | - | - | ||
| 12 040 | - | - | ||
| 540 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 128 540 | 128 540 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 128 540 | 128 540 | 0 | 0 |